Enveric Biosciences, Inc. products

Every molecule in the Psybrary™ is screened through PsyAITM, a proprietary artificial intelligence (AI) tool. Leveraging AI systems reduces the time and cost of commercial development. It streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these patentable molecules is further screened to see how changes to its makeup alter its effects and whether the new molecule might be used to synthesize additional new molecules. New compounds of sufficient purity undergo pharmacological screening, including non-clinical (receptors/cell lines), pre-clinical (animal) and ultimately clinical (human) evaluations.

Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the same or greater therapeutic effect with a lower dose of the chemotherapeutic agent, potentially minimizing the severity of side effects.

Chemo-induced peripheral neuropathy (CIPN) is a set of symptoms caused by chemotherapeutic agents that damage the nerves outside the brain and spinal cord. These distant nerves are called peripheral nerves and carry sensations to the brain and control our arms and legs’ movement. The damage to these nerves typically results in persistent pain, abnormal sensations of tingling, numbness, pain pressure, and thermal hyperalgesia in a specific area. CIPN usually begins in the hands and feet but can move to other parts of the body. It is a serious issue affecting the quality of life of millions of patients receiving chemotherapy. Approximately 380 million people live with different types of neuropathy, the majority of them being peripheral and diabetic neuropathy, with an estimated 20 million Americans suffering from CIPN.